Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): A randomised phase 3 trial

The Lancet

Volumn 378, Issue 9807, 2011, Pages 1931-1939

  Rini, Brian I ^a   Escudier, Bernard ^b   Tomczak, Piotr ^c   Kaprin, Andrey ^d   Szczylik, Cezary ^e   Hutson, Thomas E ^f   Michaelson, M Dror ^g   Gorbunova, Vera A ^h   Gore, Martin E ⁱ   Rusakov, Igor G ^j   Negrier, Sylvie ^k   Ou, Yen Chuan ^l   Castellano, Daniel ^m   Lim, Ho Yeong ⁿ   Uemura, Hirotsugu ^o   Tarazi, Jamal ^p   Cella, David ^q   Chen, Connie ^p   Rosbrook, Brad ^p   Kim, Sinil ^p   Motzer, Robert J ^r   more..

^a TAUSSIG CANCER INSTITUTE   (United States)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^d Russian Research Centre of Roentgenology and Radiology   (Russian Federation)

^e MILITARY INSTITUTE OF MEDICINE   (Poland)

^f TEXAS ONCOLOGY   (United States)

^g MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^h Chemotherapy Department   (Russian Federation)

ⁱ ROYAL MARSDEN HOSPITAL   (United Kingdom)

^j P A Herzen Research Oncological Institute   (Russian Federation)

^k CENTRE LÉON BÉRARD   (France)

^l TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^m HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

ⁿ Samsung Medical Center   (South Korea)

^o KINDAI UNIVERSITY HOSPITAL   (Japan)

^p PFIZER INC   (United States)

^q NORTHWESTERN UNIVERSITY   (United States)

^r MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AXITINIB; BEVACIZUMAB; CYTOKINE; SORAFENIB; SUNITINIB; TEMSIROLIMUS;

ABNORMAL LABORATORY RESULT; ADULT; AGED; ALOPECIA; APPETITE; ARTHRALGIA; ARTICLE; CANCER SURVIVAL; CONSTIPATION; CONTROLLED STUDY; COUGHING; DIARRHEA; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ERUPTION; DRUG WITHDRAWAL; DYSPHONIA; FATIGUE; FEMALE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; HYPOPHOSPHATEMIA; HYPOTHYROIDISM; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NAUSEA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STOMATITIS; TRANSIENT ISCHEMIC ATTACK;

EID: 82755183572     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(11)61613-9     Document Type: Article

References (31)

1. International Agency for Research on Cancer The GLOBOCAN project: cancer incidence and mortality worldwide in 2008 http://globocan.iarc.fr/ (accessed July 6, 2011).
2. RJ Motzer, NH Bander, DM Nanus Renal-cell carcinoma N Engl J Med 335 1996 865 875
3. BI Rini Metastatic renal cell carcinoma: many treatment options, one patient J Clin Oncol 27 2009 3225 3234
4. RJ Motzer, TE Hutson, P Tomczak et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med 356 2007 115 124 (Pubitemid 46089672)
5. B Escudier, T Eisen, WM Stadler et al. Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 356 2007 125 134 (Pubitemid 46089673)
6. CN Sternberg, ID Davis, J Mardiak et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial J Clin Oncol 28 2010 1061 1068
7. B Escudier, A Pluzanska, P Koralewski et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial Lancet 370 2007 2103 2111 (Pubitemid 350296300)
8. BI Rini, O Rixe, RM Bukowski et al. AG-013736, a multi-target tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a phase 2 study of cytokine-refractory, metastatic renal cell cancer (RCC) J Clin Oncol 23 2005 Abstr 4509.
9. G Sonpavde, TE Hutson, BI Rini Axitinib for renal cell carcinoma Expert Opin Investig Drugs 17 2008 741 748 (Pubitemid 351843617)
10. AM O'Farrell, TJ Abrams, HA Yuen et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo Blood 101 2003 3597 3605 (Pubitemid 36857948)
11. TJ Abrams, LB Lee, LJ Murray, NK Pryer, JM Cherrington SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer Mol Cancer Ther 2 2003 471 478
12. KT Flaherty Sorafenib in renal cell carcinoma Clin Cancer Res 13 2007 747s 752s
13. O Rixe, RM Bukowski, MD Michaelson et al. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: A phase II study Lancet Oncol 8 2007 975 984 (Pubitemid 47629888)
14. RJ Motzer, T De la Motte Rouge, AL Harzstark et al. Axitinib second-line therapy for metastatic renal cell carcinoma (mRCC): 5-year (yr) overall survival (OS) data from a phase 2 trial J Clin Oncol 29 2011 abstr 4547.
15. Y Tomita, H Uemura, H Fujimoto et al. Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a Japanese phase II study in patients with cytokine-refractory metastatic renal cell cancer (mRCC) Ann Oncol 21 Suppl 8 2010 Abstr 902P.
16. BI Rini, G Wilding, G Hudes et al. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma J Clin Oncol 27 2009 4462 4468
17. P Therasse, SG Arbuck, EA Eisenhauer et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
18. D Cella, S Yount, H Du et al. Development and validation of the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI) J Support Oncol 4 2006 191 199 (Pubitemid 43890980)
19. D Cella, S Yount, PS Brucker et al. Development and validation of a scale to measure disease-related symptoms of kidney cancer Value Health 10 2007 285 293 (Pubitemid 47077253)
20. B Escudier, T Eisen, WM Stadler et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial J Clin Oncol 27 2009 3312 3318
21. RJ Motzer, J Bacik, LH Schwartz et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma J Clin Oncol 22 2004 454 463 (Pubitemid 41079774)
22. DY Heng, W Xie, MM Regan et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study J Clin Oncol 27 2009 5794 5799
23. I Alexandre, B Billemont, JB Meric, S Richard, O Rixe Axitinib induces paradoxical erythropoietin synthesis in metastatic renal cell carcinoma J Clin Oncol 27 2009 472 473 author reply 3-4.
24. RJ Motzer, BI Rini, RM Bukowski et al. Sunitinib in patients with metastatic renal cell carcinoma JAMA 295 2006 2516 2524 (Pubitemid 43854967)
25. B Escudier, J Roigas, S Gillessen et al. Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma J Clin Oncol 27 2009 4068 4075
26. ME Gore, RJ Jones, A Ravaud et al. Efficacy and safety of intrapatient dose escalation of sorafenib as first-line treatment for metastatic renal cell carcinoma (mRCC) J Clin Oncol 29 2011 4609
27. T Ueda, Y Imamura, A Komaru et al. Treatment outcomes of sorafenib for first line or cytokinerefractory advanced renal cell carcinoma in Japanese patients Int J Urol 17 2010 811 815
28. G Di Lorenzo, G Carteni, R Autorino et al. Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer J Clin Oncol 27 2009 4469 4474
29. JA Garcia, TE Hutson, P Elson et al. Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab Cancer 116 2010 5383 5390
30. RJ Motzer, B Escudier, S Oudard et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial Lancet 372 2008 449 456
31. BI Rini, JH Schiller, JP Fruehauf et al. Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumors Clin Cancer Res 17 2011 3841 3849